MedTrace Logo

Gabapentin Treatment of Cannabis Dependence

NCT00974376 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-06-06

Study results available
· View outcomes & findings →

Summary

This is a clinical study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.

Conditions

Interventions

DRUG

gabapentin 1200mg/day

gabapentin 1200mg/day for 12 weeks

DRUG

Placebo

1200mg/day of placebo for 12 weeks

BEHAVIORAL

Manual-guided behavioral counseling

Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • The Scripps Research Institute

    lead OTHER

Principal Investigators

  • Barbara J Mason, Ph.D. · The Scripps Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-04
Primary Completion
2016-05-19
Completion
2016-05-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974376 on ClinicalTrials.gov